Date: 5th November, 2026

To,
National Stock Exchange of India Limited
"Exchange Plaza", C-1, Block G,
Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051

Dear Sir / Madam,

Sub: Integrated Filing (Financial) for the Half Year ended on 30th September, 2026
Ref: Security Id: WALPAR | ISIN: INE0G2G01015

Pursuant to the Securities and Exchange Board of India Circular No SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated March 31, 2025, please find attached the Integrated Filing (Financial) for the Half Year ended September 30, 2026.

Kindly take the same on your record and oblige us.

For, Walpar Nutritions Limited

KALPESH LADHAWALA

Digitally signed by KALPESH LADHAWALA
DN: c=IN, postalCode=380060, st=GUJARAT, street=501 AVADH 28 ,OPP SAUMYA FLAT, , AHMEDABAD,SOLA, 380060, l=AHMEDABAD, o=Personal, serialNumber=3b9936a5214b61800ed58d7705c0c2b33434ab4887 68a4386bfbfa06b7ac1ed6, pseudonym=84107bc1ed674b4391Sa41baf65d2013, 2.5.4.20=2f1f981b29f43eaf85abd1a48dffc3d65f1013a6f6db5c3e38 1791e8a6c605f74c, email=KALPESHg@WALPARNUTRITIONS.IN, cn=KALPESH LADHAWALA
Date: 2026.11.05 19:51:22 +05'30'

Kalpesh Ladhawala
Managing Director
DIN: 02849232

A Y & COMPANY
505, Fifth Floor, ARG Corporate Park
Gopal Bari, Ajmer Road, Jaipur (Raj.)
TEL NO. - +91-9649687300,
Email: info@aycompany.co.in

Limited Review Report on the Half year ended Un-audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, As Amended

Review Report

To

The Board of Directors
Walpar Nutritions Limited

1. We have reviewed the accompanying statement of unaudited Standalone financial results of **Walpar Nutritions Limited** (the 'Company') for the Half Year ended on September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 and Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019 ('the Circular').


2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Accounting Standard 25, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

A Y & COMPANY
505, Fifth Floor, ARG Corporate Park
Gopal Bari, Ajmer Road, Jaipur (Raj.)
TEL NO. - +91-9649687300,
Email: info@aycompany.co.in

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Standalone financial results, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A Y & Company
Chartered Accountants
FRN: 020829C



Akanksha Gupta
Partner
M. No. 421545
UDIN – 26421545SJVLBM6452

Place: Jaipur
Date: 05.11.2026

WALPAR NUTRITIONS LIMITED

CIN - L24230GJ2020PLC118662
2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India
Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com
Standalone Statement of Unaudited Financial Results for the Half Year ended on September 30, 2026 Pursuant to regulation 33 of SEBI (LODR) Regulation, 2015

(Amount in Lakhs)

	Particulars	Half Year ended on 30/09/2026	Half Year ended on 31/03/2026	Half Year ended on 30/09/2025	Year to date figures for the year ended 30/09/2026	Year to date figures for the year ended 30/09/2025	Year to date figures for the year ended 31/03/2026
		Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
	INCOME FROM OPERATIONS						
I	Revenue from Operations	2942.40	3657.76	2872.12	2942.40	2872.12	6529.88
II	Other Income	31.69	6.29	7.60	31.69	7.60	13.88
III	**Total Revenue (I+II)**	**2974.09**	**3664.05**	**2879.72**	**2974.09**	**2879.72**	**6543.77**
IV	**EXPENSES**						
	Cost of Material Consumed	2689.56	3349.33	2632.13	2689.56	2632.13	5981.46
	Purchase of Stock in Trade		0.00	0.00	0.00	0.00	0.00
	Change in inventories of Finished Goods, Work-in-progress & Stock in Trade	-47.07	(76.34)	(103.91)	-47.07	-103.91	-180.25
	Employee Benefit Expenses	82.66	96.02	86.92	82.66	86.92	182.94
	Finance Cost	8.73	7.31	1.22	8.73	1.22	8.53
	Depreciation &Amortization Expense	19.38	19.87	23.55	19.38	23.55	43.41
	Other Expenses	117.10	139.55	116.14	117.10	116.14	255.69
	Total expenses (IV)	**2870.35**	**3535.73**	**2756.07**	**2870.35**	**2756.07**	**6291.79**
V	**Profit before Exceptional & Extraordinary Items and tax (III-IV)**	**103.74**	**128.32**	**123.66**	**103.74**	**123.66**	**251.98**
VI	Exceptional Items			-		-	-
VII	**Profit before Extraordinary Items and tax (V-VI)**	**103.74**	**128.32**	**123.66**	**103.74**	**123.66**	**251.98**
VIII	Prior Period Items	0.00	0.00	0.00	0.00	0.00	0.00
IX	**Profit before tax (VII-VIII)**	**103.74**	**128.32**	**123.66**	**103.74**	**123.66**	**251.98**
X	**Tax Expenses**						
	1 Current Tax	26.70	32.29	31.38	26.70	31.38	63.66
	2 Deferred Tax	6.51	(0.07)	(7.62)	6.51	-7.62	(7.69)
	3 Tax Related to Earlier Years	0.00	(0.52)	-	0.00	0.00	(0.52)
	Total Tax Expenses (X)	**33.21**	**31.69**	**23.76**	**33.21**	**23.76**	**55.45**
XI	**Profit/(Loss) for the period from continuing operations (IX-X)**	**70.53**	**96.63**	**99.90**	**70.53**	**99.90**	**196.53**
XII	Profit/(Loss) from discontinuing operation	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	**Profit/(Loss) from discontinuing operation after tax (XII-XIII)**	-	-	-	-	-	-
XV	**Profit(Loss) for the Period (XI+XIV)**	**70.53**	**96.63**	**99.90**	**70.53**	**99.90**	**196.53**
XVI	**Paid up Equity Share Capital**	**939.04**	**939.04**	**939.04**	**939.04**	**939.04**	**939.04**
XVII	**Reserves & Surplus**	**829.61**	**759.08**	**661.96**	**829.61**	**661.96**	**759.08**
XVIII	Earnings per equity share						
	(1) Basic	0.75	1.03	1.06	0.75	1.06	2.09
	(2) Diluted	0.75	1.03	1.06	0.75	1.06	2.09

Notes:-

1. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on November 5, 2026
2. The Statutory Auditors of the Company have carried out the Limited Review of the above financial results of the Company and have expressed an unmodified opnion on these Results.
3. There are no investor complaints received/pending as on September 30, 2026
4. Previous year's/ period figures have been regrouped/ reclassified/ restated, wherever necessary to confirm to classification of current year/period.
5. AS 17 Relating to Segment wise reporting is not applicable as the Company operates in only One Primary segment i.e Manufacturing and Trading of Pharmaceutical, Nutraceutical, Herbal and Ayurvedic Commodities

For Walpar Nutritions Limited

WALPAR NUTRITIONS LTD.

DIRECTOR

Kalpesh P Ladhawala
Managing Director
DIN : 02849232

Place : Gandhinagar
Date : November 5, 2026

WALPAR NUTRITIONS LIMITED

CIN - L24230GJ2020PLC118662

2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Standalone Statement of Assets & Liabilities as on September 30, 2026

(Amount in Lakhs)

	Particulars	As on 30th September 2026 Unaudited	As on 31st March 2026 Audited
I.	**EQUITY AND LIABILITIES**		
1	**Shareholders' funds**		
	Share capital	939.04	939.04
	Reserves and surplus	829.61	759.08
		1,768.66	**1,698.13**
2	**Non-current liabilities**		
	Long Term Borrowings	37.58	-
	Deferred Tax Liabilities (Net)	0.64	
	Other Long Term Liabilities	-	-
	Long Term Provision	-	-
		38.22	**-**
3	**Current liabilities**		
	Short Term Borrowings	242.72	190.87
	Trade Payables		
	(i) Total outstanding dues of micro enterprises and small enterprises		-
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,138.81	1,714.64
	Other Current Liabilities	279.71	325.12
	Short Term Provisions	26.70	63.66
		1,687.93	**2,294.30**
	TOTAL	**3,494.82**	**3,992.43**
II.	**ASSETS**		
	Non-current assets		
	Property Plant & Equipments		
1	Fixed assets		
	(i) Tangible Assets	254.30	242.85
	(ii) Intangible Assets	8.35	9.00
	(iii) Intangible Assets Under Development	5.85	4.80
	Non Current Investments	521.09	506.09
	Long Term Loans & Advances	269.92	258.12
	Deferred Tax Assets	-	5.87
	Other Non Current Assets	3.39	4.41
		1,062.91	**1,031.14**
2	**Current assets**		
	Current Investments		-
	Inventories	895.35	757.88
	Trade Receivables	1,415.51	1,990.65
	Cash and cash equivalents	5.22	85.63
	Short Term Loans & Advances	109.01	91.96
	Other Current Assets	6.84	35.19
		2,431.93	**2,961.31**
	TOTAL	**3,494.82**	**3,992.43**

For Walpar Nutritions Limited

WALPAR NUTRITIONS LTD.

DIRECTOR

Kalpesh P Ladhawala
Managing Director
DIN : 02849232

Place : Gandhinagar
Date : November 5, 2026

WALPAR NUTRITIONS LIMITED

CIN - L24230GJ2020PLC118662

2nd Floor LS:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Standalone Statement of Cash Flows for the year ended on September 30, 2026

(Amount in Lakhs)

Particulars	For the Year Ended on 30.09.2026	For the Year Ended on 30.09.2025
Cash flows from operating activities		
Profit before taxation	103.74	123.66
Adjustments for:		
Depreciation & Amortization Expenses	19.38	23.55
Investment income	-	-
Prior Period Items/Non Cash Items - Preliminary Exp	-	(0.51)
Finance Cost	8.73	1.22
Working capital changes:		
(Increase) / Decrease in Trade Receivables	575.14	(247.57)
(Increase) / Decrease in Short Term Loans & Advances	(17.05)	(35.36)
(Increase) / Decrease in Other Current Assets	28.35	24.24
(Increase) / Decrease in Inventories	(137.47)	(204.14)
Increase / (Decrease) in Trade Payables	(575.84)	192.95
Increase / (Decrease) in Other Current Liabilities	(45.41)	132.09
Cash generated from operations	**(40.42)**	**10.13**
Payment/Adjustmen on Account of Tax Expenses	(63.66)	(59.95)
Net cash from operating activities	**(104.09)**	**(49.82)**
Cash flows from investing activities		
Purchase of property, plant and equipment	(31.23)	(44.71)
Investment Income	-	-
Proceeds/(Payment) for Long Term Loans & Advances	(11.81)	-
(Increase)/Decrease in Other Non Current Assets	1.02	(0.50)
Increase in Non Current Investments	(15.00)	(36.25)
Net cash used in investing activities	**(57.02)**	**(81.46)**
Cash flows from financing activities		
Proceeds/ (Repayment) of Short term Borrowings	51.85	21.16
Proceeds/ (Repayment) of Long term Borrowings	37.58	-
Proceeds from Share Capital	-	-
Proceeds from Securities Premium	-	-
Payment of Finance cost	(8.73)	(1.22)
Net cash used in financing activities	**80.69**	**19.94**
Net increase in cash and cash equivalents	**(80.41)**	**(111.34)**
Cash and cash equivalents at beginning of period	**85.63**	**150.72**
Cash and cash equivalents at end of period	**5.22**	**39.38**

For Walpar Nutritions Limited

WALPAR NUTRITIONS LI...

DIRECTOR

Kalpesh P Ladhawala
Managing Director
DIN : 02849232

Place : Gandhinagar
Date : November 5, 2026

A Y & COMPANY
505, Fifth Floor, ARG Corporate Park
Gopal Bari, Ajmer Road, Jaipur (Raj.)
TEL NO. - +91-9649687300,
Email: info@aycompany.co.in

Limited Review Report on the Half year ended Un-audited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, As Amended

Review Report

To

The Board of Directors
Walpar Nutritions Limited

1. We have reviewed the accompanying statement of unaudited Consolidated financial results of **Walpar Nutritions Limited** (the 'Company') for the Half Year ended on September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 and Circular No. CIR/CFD/CMD1/80/2019 dated July 19, 2019 ('the Circular').

2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Accounting Standard 25, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of lndia under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

4. The Statement includes the results of the following entities:


Name of Entity	Relationship
Walpar Wellness Private Limited	Subsidiary Company
Walpar Nutri Science Private Limited	Subsidiary Company
Pallota Nutritions Pvt. Ltd.	Associate Company

A Y & COMPANY
505, Fifth Floor, ARG Corporate Park
Gopal Bari, Ajmer Road, Jaipur (Raj.)
TEL NO. - +91-9649687300,
Email: info@aycompany.co.in

5. The accompanying Statement includes the Unaudited Interim Financial Results of other two Subsidiaries mentioned above whose interim financial results reflect total assets of Rs. 3,478.68 Lakhs as at September 30, 2026, and total revenue of Rs. 2699.85 Lakhs, total net profit of Rs. 164.43 Lakhs for half year ended on September 30, 2026. Audit of Walpar Wellness Pvt. Ltd. is performed by us. Further Limited Review Report of other subsidiary and associates has been submitted to us & our conclusion on the statement in so far as it relates to amounts and disclosure in the financial statements of subsidiary companies and associates is based solely on the limited review reports and procedure performed by us as stated in paragraph 3 above. Our conclusion, in so far as it relates to the affairs of such subsidiary and associates is based solely limited review reports. Our conclusion is not modified in respect of this matter.

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Consolidated financial results, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A Y & Company
Chartered Accountants
FRN: 020829C



Akanksha Gupta
Partner
M. No. 421545
UDIN – 26421545EEVMQX4023

Place: Jaipur
Date: 05.11.2026

WALPAR NUTRITIONS LIMITED

CIN - L24230GJ2020PLC118662

2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Consolidated Statement of Unaudited Financial Results for the Half Year ended on September 30, 2026 Pursuant to regulation 33 of SEBI (LODR) Regulation, 2015

(Amount in Lakhs)

	Particulars	Half Year ended on 30/09/2026	Half Year ended on 31/03/2026	Half Year ended on 30/09/2025	Year to Date Figures for Half Year ended on 30/09/2026	Year to Date Figures for Half Year ended on 30/09/2025	Year to date figures for the year ended 31/03/2026
		Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
	INCOME FROM OPERATIONS						
I	Revenue from Operations	4091.64	4229.86	3649.14	4091.64	3649.14	7879.00
II	Other Income	40.37	12.99	12.98	40.37	12.98	25.97
III	**Total Revenue (I+II)**	**4132.02**	**4242.85**	**3662.12**	**4132.02**	**3662.12**	**7904.97**
IV	**EXPENSES**						
	Cost of Material Consumed	3050.54	3347.65	2884.45	3050.54	2884.45	6232.10
	Purchase of Stock in Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Change in inventories of Finished Goods, Work-in-progress & Stock in Trade	-67.39	(171.06)	(118.66)	-67.39	-118.66	-289.72
	Employee Benefit Expenses	390.42	370.20	337.77	390.42	337.77	707.97
	Finance Cost	61.04	49.59	30.25	61.04	30.25	79.84
	Depreciation &Amortization Expense	129.35	101.52	100.25	129.35	100.25	201.77
	Other Expenses	299.88	311.81	250.89	299.88	250.89	562.70
	Total expenses (IV)	**3863.84**	**4009.71**	**3484.96**	**3863.84**	**3484.96**	**7494.66**
V	**Profit before Exceptional & Extraordinary Items and tax (III-IV)**	**268.18**	**233.14**	**177.17**	**268.18**	**177.17**	**410.31**
VI	Exceptional Items	-	-	-	-	-	-
VII	**Profit before Extraordinary Items and tax (V-VI)**	**268.18**	**233.14**	**177.17**	**268.18**	**177.17**	**410.31**
VIII	Prior Period Items	0.00	0.00	-	-	-	
IX	**Profit before tax (VII-VIII)**	**268.18**	**233.14**	**177.17**	**268.18**	**177.17**	**410.31**
X	**Tax Expenses**						
	1 Current Tax	73.27	53.23	42.24	73.27	42.24	95.47
	2 Deferred Tax	7.55	7.51	(15.28)	7.55	-15.28	(7.77)
	2 Tax Related to Earlier Years	0.00	1.91	-	-	-	1.91
	Total Tax Expenses (X)	**80.82**	**62.65**	**26.96**	**80.82**	**26.96**	**89.61**
XI	**Profit/(Loss) for the period from continuing operations (IX-X**	**187.36**	**170.49**	**150.21**	**187.36**	**150.21**	**320.70**
XII	Profit/(Loss) from discontinuing operation	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	**Profit/(Loss) from discontinuing operation after tax (XII-XII**	-	-	-	-	-	-
XV	**Profit(Loss) for the Period (XI+XIV)**	**187.36**	**170.49**	**150.21**	**187.36**	**150.21**	**320.70**
XVI	Profit/(Loss) from Associates/JV	-13.38	-20.37	0.00	-13.38	0.00	-20.37
XVII	**Profit Attributable to Minority Interest**	**49.43**	**32.16**	**20.72**	**49.43**	**20.72**	**52.88**
XVIII	**Profit Attributable to Owners of Parent**	**124.55**	**117.95**	**129.48**	**124.55**	**129.48**	**247.43**
XIX	**Paid up Equity Share Capital**	**939.04**	**939.04**	**939.04**	**939.04**	**939.04**	**939.04**
XX	**Reserves & Surplus**	**1097.87**	**950.96**	**835.99**	**1097.87**	**835.99**	**950.96**
XXI	Earnings per equity share						
	(1) Basic	1.33	1.26	1.38	1.33	1.38	2.64
	(2) Diluted	1.33	1.26	1.38	1.33	1.38	2.64

Notes:-

1. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on November 5, 2026
2. The Statutory Auditors of the Company have carried out the Limited Review of the above financial results of the Company and have expressed an unmodified opnion on these Results.
3. There are no investor complaints received/pending as on September 30, 2026
4. Previous year's/ period figures have been regrouped/ reclassified/ restated, wherever necessary to confirm to classification of current year/period.
5. AS 17 Relating to Segment wise reporting is not applicable as the Company operates in only One Primary segment i.e Manufacturing and Trading of Pharmaceutical, Nutraceutical, Herbal and Ayurvedic Commodities

For Walpar Nutritions Limited

WALPAR NUTRITIONS LTD.

DIRECTOR

Kalpesh P Ladhawala
Managing Director
DIN : 02849232

Place : Gandhinagar
Date : November 5, 2026

WALPAR NUTRITIONS LIMITED

CIN - L24230GJ2020PLC118662

2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Consolidated Statement of Assets & Liabilities as on September 30, 2026

(Amount in Lakhs)

	Particulars	As on 30th September 2026 Unaudited	As on 31st March 2026 Audited
I.	**EQUITY AND LIABILITIES**		
1	**Shareholders' funds**		
	Share capital	939.04	939.04
	Reserves and surplus	1,097.87	950.96
		2,036.91	**1,890.00**
2	**Minority Interest**	**373.83**	**324.40**
3	**Non-current liabilities**		
	Long Term Borrowings	395.72	892.61
	Deferred Tax Liabilities (Net)	1.51	-
	Other Long Term Liabilities	-	-
	Long Term Provision	-	-
		397.24	**892.61**
4	**Current liabilities**		
	Short Term Borrowings	1285.80	784.40
	Trade Payables		
	(i) Total outstanding dues of micro enterprises and small enterprises		-
	(ii) Total outstanding dues of creditors other than micro enterprises and	2000.53	2,218.92
	Other Current Liabilities	397.49	401.41
	Short Term Provisions	73.27	95.47
		3,757.09	**3,500.20**
	TOTAL	**6,565.07**	**6,607.20**
II.	**ASSETS**		
	Non-current assets		
	Property Plant & Equipments		
1	Fixed assets		
	(i) Tangible Assets	1448.54	1,177.59
	(ii) Capital Work in Progress	-	-
	(iii) Intangible Assets	9.63	10.45
	(iv) Intangible Assets Under Development	5.85	4.80
	Goodwill	32.70	32.70
	Non Current Investments	289.89	288.26
	Long Term Loans & Advances	236.62	179.02
	Deferred Tax Assets	0.00	6.01
	Other Non Current Assets	41.00	37.17
		2,064.23	**1,736.00**
2	**Current assets**		
	Current Investments		-
	Inventories	1696.59	1,526.44
	Trade Receivables	2095.96	2,345.43
	Cash and cash equivalents	36.67	493.03
	Short Term Loans & Advances	416.49	304.27
	Other Current Assets	255.13	202.02
		4,500.84	**4,871.19**
	TOTAL	**6,565.07**	**6,607.20**

For Walpar Nutritions Limited

WALPAR NUTRITIONS LTD.

DIRECTOR

Kalpesh P Ladhawala
Managing Director
DIN : 02849232

Place : Gandhinagar
Date : November 5, 2026

WALPAR NUTRITIONS LIMITED

CIN - L24230GJ2020PLC118662

2nd Floor L5:377 PLOT:5, Opp. Sabarmati, Village: Khatraj, Taluka: Kalol Gandhinagar, Gujarat - 382721 India

Website - www.walparnutritions.com; Email : finance.walpar@hotmail.com

Consolidated Statement of Cash Flows for the year ended on September 30, 2026

(Amount in Lakhs)

Particulars	For The Period Ended on 30.09.2026	For The Year Ended on 30.09.2025
Cash flows from operating activities		
Profit before taxation	**268.18**	**177.17**
Adjustments for:		
Depreciation	129.35	100.25
Investment income	-	-
Prior Period Items/Non Cash Items	8.98	3.68
Finance Cost	61.04	30.25
Working capital changes:		
(Increase) / Decrease in Trade Receivables	249.47	(405.92)
(Increase) / Decrease in Short Term Loans & Advances	(112.22)	(37.45)
(Increase) / Decrease in Other Current Assets	(53.11)	41.37
(Increase) / Decrease in Inventories	(170.15)	(248.19)
Increase / (Decrease) in Trade Payables	(218.39)	389.14
Increase / (Decrease) in Other Current Liabilities	(3.92)	106.45
Cash generated from operations	**159.23**	**156.75**
Payment/Adjustmen on Account of Tax Expenses	(95.47)	(87.43)
Net cash from operating activities	**63.76**	**69.32**
Cash flows from investing activities		
Purchase of property, plant and equipment	(400.53)	(173.60)
Investment Income	-	-
Proceeds/(Payment) for Long Term Loans & Advances	(57.60)	
(Increase)/Decrease in Non Current Investments	(1.63)	(36.25)
(Increase)/Decrease in Other Non Current Assets	(3.83)	(0.51)
Net cash used in investing activities	**(463.59)**	**(210.35)**
Cash flows from financing activities		
Proceeds/ (Repayment) of Short term Borrowings	501.40	112.09
Proceeds/ (Repayment) of Long term Borrowings	(496.89)	-48.47
Proceeds from Share Capital	-	-
Proceeds from Securities Premium	-	-
Payment of Finance cost	(61.04)	(30.25)
Net cash used in financing activities	**(56.53)**	**33.37**
Net increase in cash and cash equivalents	**(456.36)**	**(107.66)**
Cash and cash equivalents at beginning of period	**493.03**	**158.58**
Cash and cash equivalents at end of period	**36.67**	**50.91**

For Walpar Nutritions Limited

WALPAR NUTRITIONS LTD.

DIRECTOR

Kalpesh P Ladhawala
Managing Director
DIN : 02849232

Place : Gandhinagar
Date : November 5, 2026

B. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc.:

- Not Applicable

C. Format for Disclosing Outstanding Default on Loans and Debt Securities:

- Not Applicable, as there is no default in the payment of outstanding Loans / revolving facilities, Unlisted debt securities.
-

D. Format for Disclosure of Related Party Transactions (Applicable only for half-yearly filings i.e., 2nd and 4th quarter):

DISCLOSURE OF RELATED PARTY TRANSACTIONS

(Amount in Lakhs)

												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction (see Note 5)	Value of the related party transaction as approved by the audit committee (see Note 6a)	Value of transaction during the reporting period (see Note 6b)	In case monies are due to either party as a result of the transaction (see Note 1)		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7)	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
1.	Walpar Nutritions Limited	AACCW8245J	Walpar Nutri Science Private Limited	AACCW5963H	Subsidiary Company	Loan	-	1.00	2.00	1.00	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	Business operation and expansion
2			Walpar Nutri Science Private Limited	AACCW5963H	Subsidiary Company	Purchase goods or Services	-	51.77	0.00	0.00	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	Business operation and expansion
3.			Walpar Nutri Science Private Limited	AACCW5963H	Subsidiary Company	Sale of goods or Services	-	70.62	0.00	0.00	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	Business operation and expansion
4.			Walpar Wellness Private Limited	AACCW8477C	Subsidiary Company	Loan	-	44.80	76.10	31.30	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	Business operation and expansion
5.			Walpar Wellness Private Limited	AACCW8477C	Subsidiary Company	Sale of goods or Services	-	634.34	0.00	0.00	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	Business operation and expansion
6.			Walpar Wellness Private Limited	AACCW8477C	Subsidiary Company	Purchase goods or Services	-	785.21	0.00	0.00	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	Business operation and expansion
7.			Pallota Nutritions Private Limited	AAQCP0072Q	Associate Company	Loan	-	58.61	179.02	237.62	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	Business operation and expansion
8.			Pallota Nutritions Private Limited	AAQCP0072Q	Associate Company	Sale of goods or Services	-	42.16	0.00	0.00	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	Business operation and expansion
9.			Pallota Nutritions Private Limited	AAQCP0072Q	Associate Company	Purchase goods or Services	-	8.88	0.00	0.00	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	Business operation and expansion